AND EXCHANGE COMMISSION
TO SECTION 13 OR 15(D)
THE SECURITIES EXCHANGE ACT OF 1934
29, 2020 (June 29, 2020)
of Report (Date of earliest event reported)
name of registrant as specified in its charter)
or other jurisdiction
Ludlow Avenue, Northvale, New Jersey 07647
of principal executive offices)
telephone number, including area code)
(Former name or former address, if changed since last report.)
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
growth company ☐
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
June 29, 2020, Elite Pharmaceuticals, Inc. ("Elite" or the “Company") filed its annual report on Form 10-K
for the year ended March 31, 2020 and, thereafter, issued a press release announcing its financial results for that quarter. A
copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
noted in the press release, the Company will host a conference call at 11:30 AM Eastern Daylight Time (EDT) on Tuesday, June 30,
2020, to provide a general business update. Elite will respond to various stockholder questions submitted prior to the call.
June 30, 2020|
||11:00 AM EDT|
Financial questions by 7:00 AM EDT on Tuesday, June 30, 2020
Email to: email@example.com
Item 7.01 Regulation FD Disclosure.
information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report
on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, "Results of Operations and Financial Condition,"
Item 7.01, "Regulation FD Disclosure" and Item 9.01 "Financial Statements and Exhibits" of Form 8-K. As such,
the information (including the exhibit) herein shall not be deemed to be "filed" for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section,
nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless
of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing.
This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required
to be disclosed solely to satisfy the requirements of Regulation FD.
Item 9.01 Financial Statements and Exhibits.
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
June 29, 2020
||ELITE PHARMACEUTICALS, INC.
||/s/ Nasrat Hakim
Hakim, President and CEO